Casdin Capital’s GenMark Diagnostics, Inc GNMK Stock Holding History

Casdin Capital’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,365,000	Closed	-$13.9M	–	45
2020 Q1	$13.9M	Hold	3,365,000	–	–	1.47%	21
2019 Q4	$16.2M	Hold	3,365,000	–	–	1.49%	22
2019 Q3	$20.4M	Hold	3,365,000	–	–	2.11%	16
2019 Q2	$21.8M	Hold	3,365,000	–	–	2.04%	17
2019 Q1	$23.9M	Sell	3,365,000 -450,000	-12%	-$2.96M	2.62%	14
2018 Q4	$18.5M	Buy	3,815,000 +315,000	+9%	+$1.64M	3.17%	13
2018 Q3	$25.7M	Buy	3,500,000 +100,000	+3%	+$734K	3.13%	15
2018 Q2	$21.7M	Sell	3,400,000 -450,000	-12%	-$2.97M	3.03%	15
2018 Q1	$20.9M	Buy	3,850,000 +1,120,000	+41%	+$5.57M	3.68%	15
2017 Q4	$11.4M	Buy	2,730,000 +1,230,000	+82%	+$7.4M	2.77%	17
2017 Q3	$14.4M	Buy	1,500,000 +815,000	+119%	+$8.47M	4.08%	13
2017 Q2	$8.1M	Buy	685,000 +285,000	+71%	+$3.64M	3%	13
2017 Q1	$5.13M	Sell	400,000 -110,000	-22%	-$1.32M	3.03%	10
2016 Q4	$6.24M	Sell	510,000 -115,000	-18%	-$1.37M	5.16%	8
2016 Q3	$7.38M	Buy	625,000 +210,000	+51%	+$2.03M	5.97%	7
2016 Q2	$3.61M	Buy	+415,000	New	+$2.85M	3.59%	12
2016 Q1	–	Sell	-310,000	Closed	-$2.41M	–	35
2015 Q4	$2.41M	Buy	+310,000	New	+$2.38M	2.13%	17

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Casdin Capital's GNMK Position: Q2 2020 in Review

Casdin Capital sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2020, closing a stake of 3,365,000 shares — an estimated $13.9M sold.

Casdin Capital first reported a position in GNMK in Q4 2015 and held it in 17 quarters. The position peaked at $25.7M in Q3 2018. 148 funds tracked by Wall St. Rank hold GNMK as of Q2 2020.

Casdin Capital reported no remaining GenMark Diagnostics, Inc position as of Q2 2020 after selling out during the quarter.
Casdin Capital sold 3,365,000 GenMark Diagnostics, Inc shares in Q2 2020, an estimated $13.9M.
Casdin Capital first reported a position in GenMark Diagnostics, Inc in Q4 2015 and held it in 17 quarters.
Casdin Capital's GenMark Diagnostics, Inc position peaked at $25.7M in Q3 2018.
148 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2020.

Based on Casdin Capital's 13F filing for Q2 2020, filed 14 Aug 2020.